Apricitabine

From Wikipedia, the free encyclopedia

Apricitabine
Systematic (IUPAC) name
4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3- oxathiolan-4-yl]pyrimidin-2(1H)-one
Identifiers
CAS number 160707-69-7
ATC code  ?
PubChem 455041
Chemical data
Formula C8H11N3O3S 
Mol. mass 229.256 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI).

It was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold the Shire Pharmaceuticals (where the drug was called SPD754). Shire then sold the rights to develop the drug to Avexa, an Australian pharmaceutical company.[1]

[edit] References

  1. ^ AIDSmeds.com - apricitabine
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Abacavir (ABC)° • Emtricitabine° • Lamivudine (3TC)° • Tenofovir° • Didanosine • Zidovudine (AZT) • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Amdoxovir† • Stavudine‡ • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Entry/fusion inhibitors
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent.
Languages